X

Drug Profile

SYNB 1353

Alternative Names: SYNB-1353

Latest Information Update: 29 Mar 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Synlogic
Class Bacteria
Mechanism of Action Bacteria replacements; Gastrointestinal microbiome modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Homocystinuria
New Molecular Entity No

Highest Development Phases

Phase I Homocystinuria

Most Recent Events

20 Mar 2023 Pharmacodynamics data from a preclinical trial in Homocystinuria released by Synlogic
05 Jan 2023 Synlogic plans a phase II trial for Homocystinuria in USA in 2023
05 Jan 2023 SYNB 1353 receives Orphan Drug status for Homocystinuria in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com